RxDoctor Payments Data

Renee Rennick, PA

Medical · Glen Dale, WVNPI 1760530521

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 41.4% of the total. Reporting peaked in 2024 at $1,405 and has fallen 80.4% since, to $275 in 2025.

$3,929in general payments, 2019–2025

Across 162 payments — averaging $24.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$581
  • Johnson & Johnson$394
  • Phathom Pharmaceuticals, Inc.$237
  • E.r. Squibb & Sons, L.L.C.$209
  • Regeneron Healthcare Solutions, Inc.$181
  • plus $699 from 12 others

What the payments were for

  • Food & beverage$3,929100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,929 in reported general payments places this provider in the 85th percentile of 233 medical providers in West Virginia.

See all medical providers in West Virginia

Medicare billing

Part B allowed, 2024
$83,244
Medicare patients
388
Services billed
1,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib23$158,314
CreonLipase/Protease/Amylase25$64,474
LinzessLinaclotide30$24,266
Mesalamine32$8,306
Dexlansoprazole DrDexlansoprazole13$1,511
Pantoprazole Sodium117$1,153
Omeprazole93$935
Famotidine51$638
Nadolol11$507
Lactulose18$390
Dicyclomine Hcl14$220
Esomeprazole Magnesium19$140
Spironolactone15$92
Carvedilol34$71
Furosemide11$16

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Creon, Linzess$1,628$247,05478 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 233 medical providers in West Virginia.

Other medical in Glen Dale

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →